Whoops.
The novel antithrombotic vorapaxar causes intracranial hemorrhage in patients with a history of stroke, Merck announced, explaining why stroke survivors were dropped from trials of the experimental drug.

Whoops.
The novel antithrombotic vorapaxar causes intracranial hemorrhage in patients with a history of stroke, Merck announced, explaining why stroke survivors were dropped from trials of the experimental drug.

The Associated Press: Pfizer Alzheimer’s disease drug fails in study
The Boomers are aging and Alzheimer’s incidence is expected to increase. This is disappointing news.

This study was funded by GlaxoSmithKline.
The study was conducted by a physician who is a consultant for GlaxoSmithKline.

Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation (A4 Study)
I’ve added a category titled Clinical Trials. These reports will be of interest to the life underwriter but exercise caution when interpreting the results as some populations under study may be small and the findings statistically insignificant.